Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Retinal Vein Occlusion - Which Treatment When?]

A Bajor1, A Pielen1, L Danzmann1

  • 1Universitätsklinik für Augenheilkunde, Medizinische Hochschule Hannover.

Klinische Monatsblatter Fur Augenheilkunde
|April 5, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2022
Same author

[Atypical clinical course of a freshly perforated corneal ulcer].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2021
Same author

[Work sampling in ophthalmological clinical studies. A multicenter field study].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2019
Same author

Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea.

United European gastroenterology journal·2017
Same author

[Erratum to: Retinal artery occlusion].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2017
Same author

[Strategies of Intravitreal Injections with Anti-VEGF: "Pro re Nata versus Treat and Extend"].

Klinische Monatsblatter fur Augenheilkunde·2017
Same journal

Corneal Neurotisation in Neurotrophic Keratopathy: A Retrospective Analysis of Functional Outcomes and Clinical Courses.

Klinische Monatsblatter fur Augenheilkunde·2026
Same journal

Evaluating the Long-term Success and Safety of Canaloplasty in Glaucoma Patients.

Klinische Monatsblatter fur Augenheilkunde·2026
Same journal

Imbalanced Trace Elements as Risk Factors in the Pathogenesis of Glaucoma.

Klinische Monatsblatter fur Augenheilkunde·2026
Same journal

Malnutrition as a Risk Factor for Cerebral and Glaucomatous Neurodegeneration - Mechanisms and Therapeutic Strategies.

Klinische Monatsblatter fur Augenheilkunde·2026
Same journal

Impact of Wearing a Face Mask on the Reliability of Standard Automated Perimetry in Glaucoma Patients and Suspects: a Retrospective Longitudinal Study.

Klinische Monatsblatter fur Augenheilkunde·2026
Same journal

[Siderotic Cataract Eight Months After Intralenticular Metallic Foreign Body: A Case Report and Surgical Management].

Klinische Monatsblatter fur Augenheilkunde·2026
See all related articles

Intravitreal anti-VEGF therapy is effective for treating macular edema from retinal vein occlusion. Treatment decisions should prioritize optical coherence tomography (OCT) over visual acuity, with dexamethasone implants as an alternative.

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Vascular Disorders

Background:

  • Macular edema secondary to retinal vein occlusion (RVO) is a leading cause of vision loss.
  • Intravitreal therapies have revolutionized RVO management.
  • Early and consistent treatment is crucial for visual prognosis.

Purpose of the Study:

  • To review current evidence-based treatment strategies for macular edema in RVO.
  • To compare the efficacy and safety of different therapeutic modalities.
  • To highlight the importance of monitoring and adjunctive treatments.

Main Methods:

  • Review of current literature on intravitreal anti-VEGF agents (aflibercept, ranibizumab, off-label bevacizumab).
  • Discussion of treatment regimens including initial loading doses, pro-re-nata (PRN), and treat-and-extend.

Related Experiment Videos

  • Consideration of intravitreal dexamethasone implants as an alternative therapy.
  • Emphasis on optical coherence tomography (OCT) for treatment decisions.
  • Role of fluorescein angiography in identifying ischemic areas.
  • Evaluation of laser photocoagulation for ischemic retina.

    • Main Results:

    • Intravitreal anti-VEGF therapy demonstrates safety and efficacy for RVO-induced macular edema.
    • Post-initial loading doses, OCT is superior to visual acuity for guiding re-injection frequency.
    • Dexamethasone implants offer a viable alternative, considering side effect profiles like cataract progression and elevated intraocular pressure.
    • Early detection and treatment of retinal ischemia via fluorescein angiography and laser photocoagulation can reduce injection frequency and improve edema response.
    • Prompt intervention for significant retinal ischemia prevents complications such as neovascularization and secondary glaucoma.

    Conclusions:

    • Intravitreal anti-VEGF therapy, guided by OCT, is the primary treatment for RVO-related macular edema.
    • Dexamethasone implants provide an alternative therapeutic option.
    • Fluorescein angiography and timely laser treatment are essential for managing ischemic complications and optimizing outcomes.